FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2016165032> ?p ?o ?g. }

• W2016165032 endingPage "209" @default.
• W2016165032 startingPage "203" @default.
• W2016165032 abstract "Ursodeoxycholic acid (UDCA) is the first-line treatment for primary biliary cirrhosis (PBC). The long-term administration of UDCA might indirectly favor colon carcinogenesis by increasing the fecal excretion of secondary bile acids or, in contrast, it might inhibit colon carcinogenesis, as demonstrated in animal models. In patients with PBC, we examined the effect of prolonged UDCA administration on the prevalence and recurrence of colorectal adenoma and on the proliferation of colon epithelial cells. One hundred fourteen patients (103 women, 11 men; mean age, 55 years) with PBC, were enrolled in a colonoscopic surveillance program. The prevalence of colon adenoma was compared in patients already treated with UDCA (mean duration 46 months) at the time of colonoscopy (treated group, n = 52) and in patients undergoing colonoscopy just prior to treatment initiation (untreated group, n = 62). The recurrence of adenoma following removal (mean follow-up, 35 months) was compared between UDCA-treated patients and appropriate age- and gender-matched controls (2/1) selected from a cohort of 205 patients undergoing polypectomy. Epithelial cell proliferation was assessed using anti-Ki67 antibodies on colon biopsies from both treated and untreated patients. Treated and untreated patients displayed similar demographic characteristics. The prevalence of colorectal adenomas was 13% in the treated group versus 24% in the untreated group (P = .16). The colon epithelial cell proliferation index was significantly lower in treated patients than in untreated patients (P = .001). Following removal of the adenoma, the probability of recurrence was significantly lower in patients treated with UDCA than in controls (7% vs. 28% at 3 years, P = .04). In conclusion, this study suggests that, in patients with PBC, the prolonged administration of UDCA (1) is not associated with an increased prevalence of colorectal adenomas, and (2) significantly decreases the probability of colorectal adenoma recurrence following removal. These results are strengthened by the significant reduction in colon epithelial cell proliferation seen in patients treated with UDCA." @default.
• W2016165032 created "2016-06-24" @default.
• W2016165032 creator A5020985866 @default.
• W2016165032 creator A5053434760 @default.
• W2016165032 creator A5058614665 @default.
• W2016165032 creator A5061062761 @default.
• W2016165032 creator A5066266631 @default.
• W2016165032 creator A5075329486 @default.
• W2016165032 creator A5084448152 @default.
• W2016165032 creator A5088081866 @default.
• W2016165032 date "2003-07-01" @default.
• W2016165032 modified "2023-10-18" @default.
• W2016165032 title "Ursodeoxycholic acid therapy and the risk of colorectal adenoma in patients with primary biliary cirrhosis: An observational study" @default.
• W2016165032 cites W1079775 @default.
• W2016165032 cites W1892306976 @default.
• W2016165032 cites W1979241054 @default.
• W2016165032 cites W1981409857 @default.
• W2016165032 cites W1999938910 @default.
• W2016165032 cites W2002136963 @default.
• W2016165032 cites W2005393576 @default.
• W2016165032 cites W2018250093 @default.
• W2016165032 cites W2021512776 @default.
• W2016165032 cites W2027212692 @default.
• W2016165032 cites W2037692808 @default.
• W2016165032 cites W2039672525 @default.
• W2016165032 cites W2040571623 @default.
• W2016165032 cites W2063255161 @default.
• W2016165032 cites W2078244407 @default.
• W2016165032 cites W2081900895 @default.
• W2016165032 cites W2089931071 @default.
• W2016165032 cites W2094999863 @default.
• W2016165032 cites W2106815702 @default.
• W2016165032 cites W2124199533 @default.
• W2016165032 cites W2155643713 @default.
• W2016165032 cites W2324587274 @default.
• W2016165032 cites W2328253827 @default.
• W2016165032 cites W2336715068 @default.
• W2016165032 doi "https://doi.org/10.1053/jhep.2003.50311" @default.
• W2016165032 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/12830003" @default.
• W2016165032 hasPublicationYear "2003" @default.
• W2016165032 type Work @default.
• W2016165032 sameAs 2016165032 @default.
• W2016165032 citedByCount "88" @default.
• W2016165032 countsByYear W20161650322012 @default.
• W2016165032 countsByYear W20161650322013 @default.
• W2016165032 countsByYear W20161650322014 @default.
• W2016165032 countsByYear W20161650322015 @default.
• W2016165032 countsByYear W20161650322016 @default.
• W2016165032 countsByYear W20161650322017 @default.
• W2016165032 countsByYear W20161650322018 @default.
• W2016165032 countsByYear W20161650322019 @default.
• W2016165032 countsByYear W20161650322020 @default.
• W2016165032 countsByYear W20161650322021 @default.
• W2016165032 countsByYear W20161650322022 @default.
• W2016165032 countsByYear W20161650322023 @default.
• W2016165032 crossrefType "journal-article" @default.
• W2016165032 hasAuthorship W2016165032A5020985866 @default.
• W2016165032 hasAuthorship W2016165032A5053434760 @default.
• W2016165032 hasAuthorship W2016165032A5058614665 @default.
• W2016165032 hasAuthorship W2016165032A5061062761 @default.
• W2016165032 hasAuthorship W2016165032A5066266631 @default.
• W2016165032 hasAuthorship W2016165032A5075329486 @default.
• W2016165032 hasAuthorship W2016165032A5084448152 @default.
• W2016165032 hasAuthorship W2016165032A5088081866 @default.
• W2016165032 hasConcept C121608353 @default.
• W2016165032 hasConcept C126322002 @default.
• W2016165032 hasConcept C2776861080 @default.
• W2016165032 hasConcept C2777428134 @default.
• W2016165032 hasConcept C2778435480 @default.
• W2016165032 hasConcept C2779399885 @default.
• W2016165032 hasConcept C2780965833 @default.
• W2016165032 hasConcept C41260117 @default.
• W2016165032 hasConcept C526805850 @default.
• W2016165032 hasConcept C71924100 @default.
• W2016165032 hasConcept C90924648 @default.
• W2016165032 hasConceptScore W2016165032C121608353 @default.
• W2016165032 hasConceptScore W2016165032C126322002 @default.
• W2016165032 hasConceptScore W2016165032C2776861080 @default.
• W2016165032 hasConceptScore W2016165032C2777428134 @default.
• W2016165032 hasConceptScore W2016165032C2778435480 @default.
• W2016165032 hasConceptScore W2016165032C2779399885 @default.
• W2016165032 hasConceptScore W2016165032C2780965833 @default.
• W2016165032 hasConceptScore W2016165032C41260117 @default.
• W2016165032 hasConceptScore W2016165032C526805850 @default.
• W2016165032 hasConceptScore W2016165032C71924100 @default.
• W2016165032 hasConceptScore W2016165032C90924648 @default.
• W2016165032 hasIssue "1" @default.
• W2016165032 hasLocation W20161650321 @default.
• W2016165032 hasLocation W20161650322 @default.
• W2016165032 hasOpenAccess W2016165032 @default.
• W2016165032 hasPrimaryLocation W20161650321 @default.
• W2016165032 hasRelatedWork W2016165032 @default.
• W2016165032 hasRelatedWork W2074414654 @default.
• W2016165032 hasRelatedWork W2079498725 @default.
• W2016165032 hasRelatedWork W2087410669 @default.
• W2016165032 hasRelatedWork W2145028521 @default.
• W2016165032 hasRelatedWork W2896077670 @default.
• W2016165032 hasRelatedWork W2944408855 @default.

• next